Clinical trials
Chronic Leukemia clinical trials
Below are recruiting chronic leukemia clinical trials, each written for real people, not researchers. We’re tracking 303 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06792994Recruiting
CLL treatment sequence study for patients in GCLLSG trials
This observational study looks at the order of treatments given to people with chronic lymphocytic leukemia (CLL) who took part in certain first-line studies run by the German CLL Study Group. It aims to learn how different treatment sequences affect overall survival over time.
CologneAges 18–99 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06788639Recruiting
Long-term study of Breyanzi for CLL/SLL in real-world care
This study looks at people with CLL or SLL who have already been treated with the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in routine medical care. It collects information about how well the treatment works and how patients are doing over time, without giving any new treatment.
Milwaukee, WisconsinAges 18 years+ - NCT00923507Recruiting
Study of blood cancers’ natural course and next treatment needs
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Bethesda, MarylandAges 18–110 - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT03980002RecruitingPhase 2
New treatment for CLL using alternating two drug types
This trial studies an approach for people with newly diagnosed CLL/SLL (chronic lymphocytic leukemia or related disease) who need treatment. It tests whether alternating two types of chemotherapy with ibrutinib (a targeted pill) can control the disease better and safely.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04769947Recruiting
Registry for CML patients in deep remission after stopping pills
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
TurinAges 18 years+ - NCT04502394RecruitingPhase 1/Phase 2
Investigational drug combo for relapsed blood cancer
This trial combines two investigational drugs to see if they are safe and effective for patients with two types of blood cancer: diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. It may offer a new option when other treatments have not worked.
Goshen, IndianaAges 18 years+ - NCT04908228RecruitingPhase 2
Fixed treatment with ibrutinib and obinutuzumab for untreated CLL
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
Milan, MIAges 18 years+ - NCT05694312RecruitingPhase 2
Ibrutinib for anemia caused by immune destruction in CLL/SLL
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
FlorenceAges 18 years+ - NCT07874451Recruiting
Study of BCL-2 inhibitor treatments for chronic lymphocytic leukemia
This study looks at real-world experiences of people with chronic lymphocytic leukemia (CLL) who have used or are using a type of targeted therapy called a BCL-2 inhibitor. It aims to understand how well these treatments work and their side effects in everyday practice.
Nanjing, JiangsuAges 18 years+ - NCT06218628RecruitingPhase 1
Pacritinib and talazoparib for bone marrow cancers unresponsive to prior therapy
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT07774390Recruiting
Long-term outcomes of ibrutinib and venetoclax for CLL
This study looks at the long-term effects of taking ibrutinib and venetoclax together for chronic lymphocytic leukemia (CLL). It aims to see how well this treatment works over time and how it affects patients.
MilanAges Any age - NCT07751783Recruiting
Exercise program for cancer survivors
This trial helps people who have finished cancer treatment start a supervised exercise routine to improve their health. It tests whether a structured program with professional guidance is safe and helpful.
Kaohsiung, TaiwanAges 18–80 - NCT06130787Recruiting
Using your body's age to personalize CML treatment
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
AnnecyAges 18 years+ - NCT07727083Recruiting
Study of EBV-positive T/NK-cell lymphoma and related diseases
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07671378RecruitingPhase 2
Study of zanubrutinib plus sonrotoclax for high-risk CLL/SLL
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
Nanjing, JiangsuAges 18–75 - NCT07651878RecruitingPhase 1
Vididencel immunotherapy for chronic myeloid leukemia with minimal residual disease
This study tests whether an experimental immune therapy called vididencel can help patients with chronic myeloid leukemia (CML) who have responded partially to standard tyrosine kinase inhibitor (TKI) drugs. The goal is to see if this therapy can further reduce the cancer cells remaining in their body.
BergenAges 18 years+ - NCT06724536Recruiting
Study of gut bacteria and TKIs in chronic myeloid leukemia
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
TorinoAges 18 years+ - NCT07520006RecruitingPhase 1/Phase 2
NX-5948 With Other Drugs for B-cell Blood Cancers
This early-stage study tests a new drug called NX-5948, given alongside other cancer treatments, for adults with B-cell lymphomas and leukemias (including chronic lymphocytic leukemia, or CLL). The goal is to see if this combination helps control the disease, especially in patients whose cancer has come back or stopped responding to prior treatments.
Aurora, ColoradoAges 18 years+ - NCT07516093RecruitingPhase 3
Comparing two drugs for advanced CLL or SLL
This trial tests whether NX-5948 is more effective than pirtobrutinib for people with CLL or SLL whose disease has gotten worse after an earlier BTK inhibitor treatment. It aims to find a better option for those who have already tried one type of therapy.
Macon, GeorgiaAges 18 years+ - NCT07487428Recruiting
Diet study for early-stage CLL
This study tests whether a whole-food plant-based diet for 4 weeks can affect immune function and metabolism in people with early-stage CLL who have not yet had treatment.
München, BavariaAges 18 years+ - NCT07428707RecruitingEarly Phase 1
Study of pirtobrutinib in first-line CLL/SLL
This study tests a new oral medication called pirtobrutinib in people with previously untreated CLL or SLL. Researchers will collect blood and lymph node samples to understand how the immune system responds to the drug.
Bethesda, MarylandAges 18–100
Hear when a new Chronic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic leukemia?
- Yes. Clin2 currently lists 303 recruiting chronic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.